Veritas In Silico Advances mRNA-Targeted Small Molecule Drug Discovery with AI Platform ‘aibVIS,’ Bolstering European Collaborations

Investing.com (Fisco提供) Japan

Overview

Japanese biotech Veritas In Silico (VIS) is spearheading mRNA-targeted small molecule drug discovery using its proprietary AI platform, “aibVIS.” This platform integrates in silico RNA structure analysis with multiple rule-based AI, enabling pharmaceutical companies to efficiently discover mRNA-targeted small molecules for diverse diseases, leveraging existing infrastructure. VIS is also developing its own pipeline, announcing its first nucleic acid drug candidate in 2025. In January 2026, the company expanded its European collaborations by partnering with SpiroChem AG in Switzerland for joint research on mRNA-targeted compounds.

In Depth

Background

Traditional drug discovery approaches have primarily focused on protein targets. However, with the realization that approximately 80% of the human genome consists of “non-coding regions” that do not translate into proteins, RNA molecules like mRNA are gaining traction as novel drug targets. RNA, beyond being a precursor to proteins, possesses diverse intrinsic functions, offering potential new therapeutic avenues for diseases difficult to address with protein-targeted methods. Nevertheless, the complex three-dimensional structures of RNA molecules have made in silico analysis and the design of small molecules that bind to them exceedingly challenging. Veritas In Silico (VIS), a Japanese biotech company, is endeavoring to overcome this obstacle with AI technology.

Key Findings / Results

Veritas In Silico (VIS) is intensively focusing on advancing mRNA-targeted small molecule drug discovery, anchored by its proprietary AI drug discovery platform, “aibVIS.” This “aibVIS” platform represents a sophisticated integration of advanced in silico RNA structure analysis technology with multiple rule-based AI and other drug discovery techniques. This comprehensive approach enables pharmaceutical companies to efficiently discover mRNA-targeted small molecule drugs for a wide range of disease areas, all while leveraging their existing drug discovery infrastructure and compound libraries. A key technical strength of aibVIS lies in its ability to accurately predict binding sites for small molecules on complex RNA structures, which was previously challenging, and to design compounds with high binding affinity.

In parallel with its platform-as-a-service partnership business model, VIS is also actively progressing its internal pipeline development. In 2025, the company announced its first nucleic acid drug candidate. Furthermore, VIS is strengthening its international collaborations; in January 2026, it signed a Memorandum of Understanding with SpiroChem AG, a Switzerland-based specialist in medicinal chemistry, for joint research on mRNA-targeted compounds. This partnership aims to expand VIS’s R&D network in Europe and accelerate the creation of novel therapeutic candidates targeting mRNA.

Technical Significance & Outlook

Veritas In Silico’s “aibVIS” AI drug discovery platform is paving the way for the robust utilization of RNA as a novel drug target. This significantly increases the likelihood of developing small molecule therapeutic options for diseases that have been difficult to treat, particularly conditions intractable with protein-targeted approaches. Pharmaceutical companies can expect reduced development risks and costs, as they can efficiently acquire novel lead compounds in a shorter timeframe while optimizing their existing capital investments. The European partnership with SpiroChem AG will enhance VIS’s global presence and foster international exchange of technology and knowledge.

VIS’s hybrid business model (platform provision alongside internal pipeline development) indicates a strategic evolution towards becoming a specialty pharma company encompassing research, development, and commercialization. The future challenge lies in demonstrating clinical success for AI-designed compounds and establishing their efficacy and safety. mRNA-targeted small molecule drugs represent a distinct approach from other nucleic acid therapeutics (e.g., siRNA, ASO) and potentially offer advantages such as oral bioavailability, positioning them as a next-generation frontier in drug discovery whose progress will be closely watched.